A Silymarin Antioxidant Serum Improves Facial Acne Alone and as Part of a Treatment Regimen
CONCLUSION: Silymarin is shown in clinical testing to have significant benefits in reducing lipid peroxidation, oiliness, and PIH, and in improving key markers of skin aging. Additionally, the serum can be used alone or as an adjunctive treatment in acne therapy to further benefit aging, acne-prone skin. J Drugs Dermatol. 2024;23(4): doi:10.36849/JDD.8120.PMID:38564394 | DOI:10.36849/JDD.8120 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Source Type: research
Clinical Impacts of Omalizumab on the Psychiatric Comorbidities of Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis
J Drugs Dermatol. 2024 Apr 1;23(4):e116-e117. doi: 10.36849/JDD.7919.NO ABSTRACTPMID:38564395 | DOI:10.36849/JDD.7919 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Marcus G Tan Adrian M J Bailey Brian Dorus Mark G Kirchhof Source Type: research
COVID-19 Protection Strategies: Lessons Learned About Epidermal Barrier Function and the Significance of Optimized Skin Care
J Drugs Dermatol. 2024 Apr 1;23(4):244-248. doi: 10.36849/JDD.7862.ABSTRACTInitially categorized as primarily a respiratory disease, COVID-19 can involve other organ systems and may have direct skin manifestations, including exanthems, morbilliform eruption, generalized urticaria, or pseudo-chilblains —commonly called “COVID Toes.” Frequent handwashing and prolonged wearing of face masks and shields in efforts to minimize transmission of SARS-CoV-2, the novel coronavirus that causes COVID, has given rise to indirect skin manifestations of COVID. “Maskne” and handwashing der...
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Leon Kircik James Q Del Rosso Source Type: research
Dermatologists' Perspectives on Biosimilars
Conclusion: Biosimilars are safe and effective for treating approved dermatological conditions and may lower patient costs compared to their reference products. Patients are not always offered biosimilar therapy as an option, which may be due to unfamiliarity among dermatologists. This survey suggests a need for more research and educational initiatives, such as modules and workshops that focus on biosimilar safety, efficacy, and interchangeability guidelines. J Drugs Dermatol. 2024;23(4):doi:10.36849/JDD.7755.PMID:38564397 | DOI:10.36849/JDD.7755 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Priscila Arellano Zameza Christina Kontzias Keith Flanders Peter Sonnenreich Steven R Feldman Source Type: research
Expression of IL-4 in Tumors: A Safety Surrogate to Predict Cancer Survival Associated With Biologic Therapies
J Drugs Dermatol. 2024 Apr 1;23(4):e118-e119. doi: 10.36849/JDD.7941.NO ABSTRACTPMID:38564398 | DOI:10.36849/JDD.7941 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Nikolai Klebanov Carly Grant Jeffrey S Smith Lourdes M Perez-Chada Joseph F Merola Source Type: research
